Literature DB >> 19170786

Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Sarra Nazem1, Andrew D Siderowf, John E Duda, Tom Ten Have, Amy Colcher, Stacy S Horn, Paul J Moberg, Jayne R Wilkinson, Howard I Hurtig, Matthew B Stern, Daniel Weintraub.   

Abstract

OBJECTIVES: To examine Montreal Cognitive Assessment (MoCA) performance in patients with Parkinson's disease (PD) with "normal" global cognition according to Mini-Mental State Examination (MMSE) score.
DESIGN: A cross-sectional comparison of the MoCA and the MMSE.
SETTING: Two movement disorders centers at the University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center. PARTICIPANTS: A convenience sample of 131 patients with idiopathic PD who were screened for cognitive and psychiatric complications. MEASUREMENTS: Subjects were administered the MoCA and MMSE, and only subjects defined as having a normal age- and education-adjusted MMSE score were included in the analyses (N=100). As previously recommended in patients without PD, a MoCA score less than 26 was used to indicate the presence of at least mild cognitive impairment (MCI).
RESULTS: Mean MMSE and MoCA scores+/-standard deviation were 28.8+/-1.1 and 24.9+/-3.1, respectively. More than half (52.0%) of subjects with normal MMSE scores had cognitive impairment according to their MoCA score. Impairments were seen in numerous cognitive domains, including memory, visuospatial and executive abilities, attention, and language. Predictors of cognitive impairment on the MoCA using univariate analyses were male sex, older age, lower educational level, and greater disease severity; older age was the only predictor in a multivariate model.
CONCLUSION: Approximately half of patients with PD with a normal MMSE score have cognitive impairment based on the recommended MoCA cutoff score. These results suggest that MCI is common in PD and that the MoCA is a more sensitive instrument than the MMSE for its detection.

Entities:  

Mesh:

Year:  2008        PMID: 19170786      PMCID: PMC2754699          DOI: 10.1111/j.1532-5415.2008.02096.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  29 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Memory and executive function impairment predict dementia in Parkinson's disease.

Authors:  Gilberto Levy; Diane M Jacobs; Ming-Xin Tang; Lucien J Côté; Elan D Louis; Brenda Alfaro; Helen Mejia; Yaakov Stern; Karen Marder
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

3.  The meaning of cognitive impairment in the elderly.

Authors:  M Folstein; J C Anthony; I Parhad; B Duffy; E M Gruenberg
Journal:  J Am Geriatr Soc       Date:  1985-04       Impact factor: 5.562

4.  Dementia in Parkinson disease: a neuropsychological analysis.

Authors:  F J Pirozzolo; E C Hansch; J A Mortimer; D D Webster; M A Kuskowski
Journal:  Brain Cogn       Date:  1982-01       Impact factor: 2.310

5.  Neuropsychological profile of patients with Parkinson's disease without dementia.

Authors:  Carmen Janvin; Dag Aarsland; Jan P Larsen; Kenneth Hugdahl
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

6.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

Authors:  Dag Aarsland; Kjeld Andersen; Jan P Larsen; Anette Lolk; Per Kragh-Sørensen
Journal:  Arch Neurol       Date:  2003-03

7.  A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.

Authors:  Cindy Zadikoff; Susan H Fox; David F Tang-Wai; Teri Thomsen; Rob M A de Bie; Pettarusup Wadia; Janis Miyasaki; Sarah Duff-Canning; Anthony E Lang; Connie Marras
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

8.  A longitudinal study of neuropsychological change in individuals with Parkinson's disease.

Authors:  Tamiko Azuma; Robyn F Cruz; Kathryn A Bayles; Cheryl K Tomoeda; Erwin B Montgomery
Journal:  Int J Geriatr Psychiatry       Date:  2003-11       Impact factor: 3.485

9.  Assessment of cognition in Parkinson's disease.

Authors:  J Marinus; M Visser; N A Verwey; F R J Verhey; H A M Middelkoop; A M Stiggelbout; J J van Hilten
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

10.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

Authors:  Thomas Foltynie; Carol E G Brayne; Trevor W Robbins; Roger A Barker
Journal:  Brain       Date:  2003-12-22       Impact factor: 13.501

View more
  84 in total

1.  Screening for DSM-IV-TR cognitive disorder NOS in Parkinson's disease using the Mattis Dementia Rating Scale.

Authors:  Gregory M Pontone; Justin Palanci; James R Williams; Susan Spear Bassett
Journal:  Int J Geriatr Psychiatry       Date:  2012-05-24       Impact factor: 3.485

Review 2.  Parkinson's disease dementia.

Authors:  Mary J Docherty; David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 3.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

4.  Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA.

Authors:  B Hanna-Pladdy; A Enslein; M Fray; B J Gajewski; R Pahwa; K E Lyons
Journal:  Int J Neurosci       Date:  2010-08       Impact factor: 2.292

Review 5.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

6.  A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Authors:  Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

7.  Can we improve clinical prediction of at-risk older drivers?

Authors:  Alex R Bowers; R Julius Anastasio; Sarah S Sheldon; Margaret G O'Connor; Ann M Hollis; Piers D Howe; Todd S Horowitz
Journal:  Accid Anal Prev       Date:  2013-07-16

Review 8.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

9.  Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis.

Authors:  Ping Liu; Tao Feng; Yong-jun Wang; Xuan Zhang; Biao Chen
Journal:  J Zhejiang Univ Sci B       Date:  2011-09       Impact factor: 3.066

10.  Cognitive performance on the mini-mental state examination and the montreal cognitive assessment across the healthy adult lifespan.

Authors:  Shea Gluhm; Jody Goldstein; Kiet Loc; Alexandra Colt; Charles Van Liew; Jody Corey-Bloom
Journal:  Cogn Behav Neurol       Date:  2013-03       Impact factor: 1.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.